Quick Answer
MBX Biosciences, Inc. reported Stockholders Equity of $369.22 million for the year ending 2025.
- MBX Biosciences, Inc. showed an increase of +43.4% in Stockholders Equity from 2024 to 2025.
- This data is from MBX Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$48.27 million | Q2 2023: -$55.39 million | Q3 2023: -$64.82 million | Q1 2024: -$83.05 million | Q2 2024: -$97.89 million | Q3 2024: $271.37 million | Q1 2025: $235.42 million | Q2 2025: $219.24 million | Q3 2025: $387.54 million.
- Over the full 4 years of available data (2022 to 2025), MBX Biosciences, Inc.'s Stockholders Equity has grown by 966.6%.
- Historical annual values: Fiscal year 2025: $369.22 million | Fiscal year 2024: $257.44 million | Fiscal year 2023: -$72.47 million | Fiscal year 2022: -$42.61 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: